Biopharmaceutical

Biopharmaceutical research is skilled and labor-intensive.

Will Washington Find the Cure for Cancer? Kenneth C. Frazier 2011

• Biopharmaceutical company Horizon Pharma Inc. didn't make great gains on its IPO, but its ability to even get the deal done is noteworthy, given that it has never been profitable and carries a warning from its auditor about its ability to remain in business.

Teavana IPO Rises 64% in Busy Week of Debuts Lynn Cowan 2011

Biopharmaceutical company Idenix Pharmaceuticals Inc. on Monday reported positive interim data from a clinical trial of its lead hepatitis C drug candidate and said it is advancing its hepatitis C development pipeline.

Idenix Reports Positive Interim Data for Hepatitis C Drug Ben Fox Rubin 2012

Biopharmaceutical developer Vical said it would get a $130 million upfront payment from Japan's Astellas Pharma in a new licensing deal to develop and sell its TransVax vaccine.

Google, M&A Boost Stocks Steven Russolillo 2011

Biopharmaceutical company Inhibitex said it saw favorable results in clinical trials of a drug aimed at treating infections caused by the hepatitis C virus.

Dow Snaps Win Streak Brendan Conway 2011

Biopharmaceutical firm Verastem Inc. climbed in early trading after boosting the size of its deal.

Verastem Climbs Post-IPO Lynn Cowan 2012

Biopharmaceutical company Orexigen Therapeutics fell 63 cents, or 11%, to 5.10 after lowering the previously reported number of patients who lost certain levels of weight in a trial for its Contrave antiobesity treatment.

Puerto Rican Banks Climb, But Compass Loses Ground Kristina Peterson 2010

Biopharmaceutical company Orexigen Therapeutics fell 63 cents, or 11%, to 5.10 after lowering the previously reported number of patients who lost certain levels of weight in a trial for its Contrave antiobesity treatment.

Puerto Rican Banks Climb, But Compass Loses Ground Kristina Peterson 2010

Biopharmaceutical company Novavax jumped 25 cents, or 11%, to 2.59 after the first stage of a trial studying the Rockville, Md., company's pandemic influenza vaccine showed that safety and immunogenicity, or the ability to invoke an immune response, were consistent among the entire 1,000-person study population.

Robbins Drops 6.6%, and MedCath Slides Kristina Peterson 2010

Biopharmaceutical company Orexigen Therapeutics fell 63 cents, or 11%, to 5.10 after lowering the previously reported number of patients who lost certain levels of weight in a trial for its Contrave antiobesity treatment.

Puerto Rican Banks Climb, But Compass Loses Ground Kristina Peterson 2010